Direct reprogramming of fibroblasts into myocytes to reverse fibrosis

Annual Review of Physiology

Volumn 76, Issue , 2014, Pages 21-37

  Muraoka, Naoto ^a   Ieda, Masaki ^a,b  

^a KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b JAPAN SCIENCE AND TECHNOLOGY AGENCY   (Japan)

Author keywords

Cardiac regeneration; Heart; Heart failure; Induced cardiomyocytes; Stem cell

Indexed keywords

ANIMALS; FIBROSIS; HEART DISEASES; HEART FAILURE; HUMANS; MICE; MICRORNAS; MYOCARDIAL INFARCTION; MYOCYTES, CARDIAC; REGENERATION; STEM CELLS;

EID: 84894144934     PISSN: 00664278     EISSN: 15451585     Source Type: Book Series    
DOI: 10.1146/annurev-physiol-021113-170301     Document Type: Review

References (111)

1. Bergmann O, Bhardwaj RD, Bernard S, Zdunek S, Barnabe-Heider F, et al. 2009. Evidence for cardiomyocyte renewal in humans. Science 324:98-1022
2. Senyo SE, Steinhauser ML, Pizzimenti CL, Yang VK, Cai L, et al. 2013. Mammalian heart renewal by pre-existing cardiomyocytes. Nature 493:433-366
3. Taylor DO, Edwards LB, Aurora P, Christie JD, Dobbels F, et al. 2008. Registry of the International Society for Heart and Lung Transplantation: twenty-fifth official adult heart transplant report -2008. J. Heart Lung Transplant. 27:943-566
4. Mummery C, Ward D, van den Brink CE, Bird SD, Doevendans PA, et al. 2002. Cardiomyocyte differentiation of mouse and human embryonic stem cells. J. Anat. 200:233-422
5. Aguirre A, Sancho-Martinez I, Izpisua Belmonte JC. 2013. Reprogramming toward heart regeneration: stem cells and beyond. Cell Stem Cell 12:275-844
6. Laflamme MA, Chen KY, Naumova AV, Muskheli V, Fugate JA, et al. 2007. Cardiomyocytes derived from human embryonic stem cells in pro-survival factors enhance function of infarcted rat hearts. Nat. Biotechnol. 25:1015-244
7. van Laake LW, Passier R, Doevendans PA, Mummery CL. 2008. Human embryonic stem cell-derived cardiomyocytes and cardiac repair in rodents. Circ. Res. 102:1008-100
8. Bolli R, Chugh AR, D'Amario D, Loughran JH, Stoddard MF, et al. 2011. Cardiac stem cells in patients with ischaemic cardiomyopathy (SCIPIO): initial results of a randomised phase 1 trial. Lancet 378:1847-577
9. Makkar RR, Smith RR, Cheng K, Malliaras K, Thomson LE, et al. 2012. Intracoronary cardiospherederived cells for heart regeneration aftermyocardial infarction(CADUCEUS):a prospective, randomised phase 1 trial. Lancet 379:895-9044
10. Shiba Y, Fernandes S, Zhu WZ, Filice D, Muskheli V, et al. 2012. Human ES-cell-derived cardiomyocytes electrically couple and suppress arrhythmias in injured hearts. Nature 489:322-255
11. Ieda M, Tsuchihashi T, Ivey KN, Ross RS, Hong TT, et al. 2009. Cardiac fibroblasts regulatemyocardial proliferation through β1 integrin signaling. Dev. Cell 16:233-444
12. Baudino TA, Carver W, Giles W, Borg TK. 2006. Cardiac fibroblasts: friend or foe? Am. J. Physiol. Heart Circ. Physiol. 291:H1015-266
13. Camelliti P, Borg TK, Kohl P. 2005. Structural and functional characterisation of cardiac fibroblasts. Cardiovasc. Res. 65:40-511
14. Weber KT, Brilla CG. 1991. Pathological hypertrophy and cardiac interstitium. Fibrosis and reninangiotensin-aldosterone system. Circulation 83:1849-655
15. Ieda M, Fu JD, Delgado-Olguin P, Vedantham V, Hayashi Y, et al. 2010. Direct reprogramming of fibroblasts into functional cardiomyocytes by defined factors. Cell 142:375-866
16. Jayawardena TM, Egemnazarov B, Finch EA, Zhang L, Payne JA, et al. 2012. MicroRNA-mediated in vitro and in vivo direct reprogramming of cardiac fibroblasts to cardiomyocytes. Circ. Res. 110:1465-733
17. Protze S, Khattak S, Poulet C, LindemannD,Tanaka EM, RavensU. 2012. A new approach to transcription factor screening for reprogramming of fibroblasts to cardiomyocyte-like cells. J. Mol. Cell. Cardiol. 53:323-322
18. Song K, Nam YJ, Luo X, Qi X, Tan W, et al. 2012. Heart repair by reprogramming non-myocytes with cardiac transcription factors. Nature 485:599-6044
19. Islas JF, Liu Y, Weng KC, Robertson MJ, Zhang S, et al. 2012. Transcription factors ETS2 and MESP1 transdifferentiate human dermal fibroblasts into cardiac progenitors. Proc. Natl. Acad. Sci. USA 109:13016-211
20. Nam YJ, Song K, Luo X, Daniel E, Lambeth K, et al. 2013. Reprogramming of human fibroblasts toward a cardiac fate. Proc. Natl. Acad. Sci. USA 110:5588-933
21. Nam YJ, Song K, Olson EN. 2013. Heart repair by cardiac reprogramming. Nat. Med. 19:413-155
22. Wada R, Muraoka N, Inagawa K, Yamakawa H, Miyamoto K, et al. 2013. Induction of human cardiomyocyte-like cells from fibroblasts by defined factors. Proc. Natl. Acad. Sci. USA 110:12667-722
23. Qian L, Huang Y, Spencer CI, Foley A, Vedantham V, et al. 2012. In vivo reprogramming of murine cardiac fibroblasts into induced cardiomyocytes. Nature 485:593-988
24. InagawaK,MiyamotoK,YamakawaH,Muraoka N, Sadahiro T, et al. 2012. Induction of cardiomyocytelike cells in infarct hearts by gene transfer of Gata4, Mef2c, and Tbx5. Circ. Res. 111:1147-566
25. Inagawa K, Ieda M. 2013. Direct reprogramming of mouse fibroblasts into cardiac myocytes. J. Cardiovasc. Transl. Res. 6:37-455
26. Davis RL, Weintraub H, Lassar AB. 1987. Expression of a single transfected cDNA converts fibroblasts to myoblasts. Cell 51:987-10000
27. Berkes CA, Tapscott SJ. 2005. MyoD and the transcriptional control of myogenesis. Semin. Cell Dev. Biol. 16:585-955
28. Visvader JE, Elefanty AG, Strasser A, Adams JM. 1992. GATA-1 but not SCL induces megakaryocytic differentiation in an early myeloid line. EMBO J. 11:4557-644
29. Heyworth C, Pearson S,May G, Enver T. 2002. Transcription factor-mediated lineage switching reveals plasticity in primary committed progenitor cells. EMBO J. 21:3770-811
30. Xie H, Ye M, Feng R, Graf T. 2004. Stepwise reprogramming of B cells into macrophages. Cell 117:663-766
31. Laiosa CV, Stadtfeld M, Xie H, de Andres-Aguayo L, Graf T. 2006. Reprogramming of committed T cell progenitors to macrophages and dendritic cells by C/EBP and PU.1 transcription factors. Immunity 25:731-444
32. Zhang P, Iwasaki-Arai J, Iwasaki H, Fenyus ML,Dayaram T, et al. 2004. Enhancement of hematopoietic stem cell repopulating capacity and self-renewal in the absence of the transcription factor C/EBP?. Immunity 21:853-633
33. Laugwitz KL, Moretti A, Lam J, Gruber P, Chen Y, et al. 2005. Postnatal isl1+ cardioblasts enter fully differentiated cardiomyocyte lineages. Nature 433:647-533
34. Srivastava D. 2006. Making or breaking the heart: from lineage determination to morphogenesis. Cell 126:1037-488
35. Bondue A, Lapouge G, Paulissen C, Semeraro C, Iacovino M, et al. 2008. Mesp1 acts as a master regulator of multipotent cardiovascular progenitor specification. Cell Stem Cell 3:69-844
36. Takeuchi JK, Bruneau BG. 2009. Directed transdifferentiation of mouse mesoderm to heart tissue by defined factors. Nature 459:708-111
37. Takahashi K, Yamanaka S. 2006. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell 126:663-766
38. Yoshida Y, Yamanaka S. 2010. Recent stem cell advances: induced pluripotent stem cells for disease modeling and stem cell-based regeneration. Circulation 122:80-877
39. Yamanaka S, Blau HM. 2010. Nuclear reprogramming to a pluripotent state by three approaches. Nature 465:704-122
40. Itzhaki I, Maizels L, Huber I, Zwi-Dantsis L, Caspi O, et al. 2011. Modelling the long QT syndrome with induced pluripotent stem cells. Nature 471:225-299
41. Tiscornia G, Monserrat N, Belmonte JC. 2011. Modelling long QT syndrome with IPS cells: Be still, my beating heart. Circ. Res. 108:648-499
42. Wu SM, Hochedlinger K. 2011. Harnessing the potential of induced pluripotent stem cells for regenerative medicine. Nat. Cell Biol. 13:497-5055
43. Song M, Paul S, Lim H, Dayem AA, Cho SG. 2012. Induced pluripotent stem cell research: a revolutionary approach to face the challenges in drug screening. Arch. Pharm. Res. 35:245-600
44. Takahashi K, Tanabe K, Ohnuki M, Narita M, Ichisaka T, et al. 2007. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell 131:861-722
45. Yu J, Vodyanik MA, Smuga-Otto K, Antosiewicz-Bourget J, Frane JL, et al. 2007. Induced pluripotent stem cell lines derived from human somatic cells. Science 318:1917-200
46. Yazawa M, Hsueh B, Jia X, Pasca AM, Bernstein JA, et al. 2011. Using induced pluripotent stem cells to investigate cardiac phenotypes in Timothy syndrome. Nature 471:230-344
47. Jaenisch R. 2012. Nuclear cloning and direct reprogramming: the long and the short path to Stockholm. Cell Stem Cell 11:744-477
48. Soldner F, Laganiere J, Cheng AW, Hockemeyer D, Gao Q, et al. 2011. Generation of isogenic pluripotent stem cells differing exclusively at two early onset Parkinson point mutations. Cell 146:318-311
49. Szabo E, Rampalli S, Risueno RM, Schnerch A, Mitchell R, et al. 2010. Direct conversion of human fibroblasts to multilineage blood progenitors. Nature 468:521-266
50. Vierbuchen T, Ostermeier A, Pang ZP, Kokubu Y, Sudhof TC,Wernig M. 2010. Direct conversion of fibroblasts to functional neurons by defined factors. Nature 463:1035-411
51. Marro S, Pang ZP, Yang N, Tsai MC, Qu K, et al. 2011. Direct lineage conversion of terminally differentiated hepatocytes to functional neurons. Cell Stem Cell 9:374-822
52. Pang ZP, Yang N, Vierbuchen T, Ostermeier A, Fuentes DR, et al. 2011. Induction of human neuronal cells by defined transcription factors. Nature 476:220-233
53. Sekiya S, Suzuki A. 2011. Direct conversion of mouse fibroblasts to hepatocyte-like cells by defined factors. Nature 475:390-933
54. Yoo AS, Sun AX, Li L, Shcheglovitov A, Portmann T, et al. 2011. MicroRNA-mediated conversion of human fibroblasts to neurons. Nature 476:228-311
55. Han DW, Tapia N, Hermann A, Hemmer K, Hoing S, et al. 2012. Direct reprogramming of fibroblasts into neural stem cells by defined factors. Cell Stem Cell 10:465-722
56. Huang P, He Z, Ji S, Sun H, Xiang D, et al. 2011. Induction of functional hepatocyte-like cells from mouse fibroblasts by defined factors. Nature 475:386-899
57. Lujan E, Chanda S, Ahlenius H, Sudhof TC,Wernig M. 2012. Direct conversion of mouse fibroblasts to self-renewing, tripotent neural precursor cells. Proc. Natl. Acad. Sci. USA 109:2527-322
58. Pfisterer U, KirkebyA,TorperO,Wood J, Nelander J, et al. 2011. Direct conversion of human fibroblasts to dopaminergic neurons. Proc. Natl. Acad. Sci. USA 108:10343-488
59. Buganim Y, Itskovich E, Hu YC, Cheng AW, Ganz K, et al. 2012. Direct reprogramming of fibroblasts into embryonic Sertoli-like cells by defined factors. Cell Stem Cell 11:373-866
60. Kim J, Su SC, Wang H, Cheng AW, Cassady JP, et al. 2011. Functional integration of dopaminergic neurons directly converted from mouse fibroblasts. Cell Stem Cell 9:413-199
61. Ieda M, Kanazawa H, Kimura K, Hattori F, Ieda Y, et al. 2007. Sema3a maintains normal heart rhythm through sympathetic innervation patterning. Nat. Med. 13:604-122
62. Zhao R, Watt AJ, Battle MA, Li J, Bondow BJ, Duncan SA. 2008. Loss of both GATA4 and GATA6 blocks cardiac myocyte differentiation and results in acardia in mice. Dev. Biol. 317:614-199
63. Ghosh TK, Song FF, Packham EA, Buxton S, Robinson TE, et al. 2009. Physical interaction between TBX5 and MEF2C is required for early heart development. Mol. Cell. Biol. 29:2205-188
64. Garg V, Kathiriya IS, Barnes R, Schluterman MK, King IN, et al. 2003. GATA4 mutations cause human congenital heart defects and reveal an interaction with TBX5. Nature 424:443-477
65. Bruneau BG, Nemer G, Schmitt JP, Charron F, Robitaille L, et al. 2001. A murine model of Holt-Oram syndrome defines roles of the T-box transcription factor Tbx5 in cardiogenesis and disease. Cell 106:709-211
66. Lin Q, Schwarz J, Bucana C, Olson EN. 1997. Control ofmouse cardiac morphogenesis and myogenesis by transcription factor MEF2C. Science 276:1404-77
67. Okita K, Ichisaka T, Yamanaka S. 2007. Generation of germline-competent induced pluripotent stem cells. Nature 448:313-177
68. Bu L, Jiang X, Martin-Puig S, Caron L, Zhu S, et al. 2009. Human ISL1 heart progenitors generate diverse multipotent cardiovascular cell lineages. Nature 460:113-177
69. Lindsley RC, Gill JG, Murphy TL, Langer EM, Cai M, et al. 2008. Mesp1 coordinately regulates cardiovascular fate restriction and epithelial- mesenchymal transition in differentiating ESCs. Cell Stem Cell 3:55-688
70. Wu SM. 2008. Mesp1 at the heart of mesoderm lineage specification. Cell Stem Cell 3:1-22
71. Srivastava D, Ieda M. 2012. Critical factors for cardiac reprogramming. Circ. Res. 111:5-88
72. Srivastava D, Cserjesi P, Olson EN. 1995. A subclass of bHLH proteins required for cardiac morphogenesis. Science 270:1995-999
73. Srivastava D, Thomas T, Lin Q, Kirby ML, Brown D, Olson EN. 1997. Regulation of cardiac mesodermal and neural crest development by the bHLH transcription factor, dHAND. Nat. Genet. 16:154-600
74. Chien KR, Yi BA, Xu H, Mummery CL. 2012. Cardiomyocyte reprogramming and the new age of cellular alchemy. J. Mol. Cell. Cardiol. 53:311-133
75. Hata A. 2013. Functions of microRNAs in cardiovascular biology and disease. Annu. Rev. Physiol. 75:69-933
76. Liu N, Olson EN. 2010. MicroRNA regulatory networks in cardiovascular development. Dev. Cell 18:510-255
77. Zhao Y, Ransom JF, Li A, Vedantham V, von Drehle M, et al. 2007. Dysregulation of cardiogenesis, cardiac conduction, and cell cycle in mice lacking miRNA-1-2. Cell 129:303-177
78. Zhao Y, Samal E, Srivastava D. 2005. Serum response factor regulates a muscle-specific microRNA that targets Hand2 during cardiogenesis. Nature 436:214-200
79. Liu N, Bezprozvannaya S, Williams AH, Qi X, Richardson JA, et al. 2008. microRNA-133a regulates cardiomyocyte proliferation and suppresses smooth muscle gene expression in the heart. Genes Dev. 22:3242-544
80. Mathison M, Gersch RP,NasserA,Lilo S, Korman M, et al. 2012. In vivo cardiac cellular reprogramming efficacy is enhanced by angiogenic preconditioning of the infarcted myocardium with vascular endothelial growth factor. J. Am. Heart Assoc. 1:e0056522
81. Carey BW, Markoulaki S, Hanna J, Saha K, Gao Q, et al. 2009. Reprogramming of murine and human somatic cells using a single polycistronic vector. Proc. Natl. Acad. Sci. USA 106:157-622
82. Srivastava D, Ieda M, Fu J, Qian L. 2012. Cardiac repair with thymosin β4 and cardiac reprogramming factors. Ann. NY Acad. Sci. 1270:66-722
83. Lee ST, White AJ, Matsushita S, Malliaras K, Steenbergen C, et al. 2011. Intramyocardial injection of autologous cardiospheres or cardiosphere-derived cells preserves function and minimizes adverse ventricular remodeling in pigs with heart failure post-myocardial infarction. J. Am. Coll. Cardiol. 57:455-655
84. Masumoto H, Matsuo T, Yamamizu K, Uosaki H, Narazaki G, et al. 2012. Pluripotent stem cell-engineered cell sheets reassembled with defined cardiovascular populations ameliorate reduction in infarct heart function through cardiomyocyte-mediated neovascularization. Stem Cells 30:1196-2055
85. Mummery CL, Lee RT. 2013. Is heart regeneration on the right track? Nat. Med. 19:412-133
86. Chen JX, Krane M, Deutsch MA, Wang L, Rav-Acha M, et al. 2012. Inefficient reprogramming of fibroblasts into cardiomyocytes using Gata4, Mef2c, and Tbx5. Circ. Res. 111:50-555
87. Polo JM, Anderssen E, Walsh RM, Schwarz BA, Nefzger CM, et al. 2012. A molecular roadmap of reprogramming somatic cells into iPS cells. Cell 151:1617-322
88. Carey BW, Markoulaki S, Hanna JH, Faddah DA, Buganim Y, et al. 2011. Reprogramming factor stoichiometry influences the epigenetic state and biological properties of induced pluripotent stem cells. Cell Stem Cell 9:588-988
89. Takahashi K, Okita K, Nakagawa M, Yamanaka S. 2007. Induction of pluripotent stem cells from fibroblast cultures. Nat. Protocol 2:3081-899
90. Buganim Y, Faddah DA, Cheng AW, Itskovich E, Markoulaki S, et al. 2012. Single-cell expression analyses during cellular reprogramming reveal an early stochastic and a late hierarchic phase. Cell 150:1209-222
91. Maherali N, Hochedlinger K. 2008. Guidelines and techniques for the generation of induced pluripotent stem cells. Cell Stem Cell 3:595-6055
92. Zhou Q, Melton DA. 2008. Extrememakeover: converting one cell into another. Cell Stem Cell 3:382-888
93. Graf T, Enver T. 2009. Forcing cells to change lineages. Nature 462:587-944
94. Vierbuchen T,WernigM. 2012. Molecular roadblocks for cellular reprogramming. Mol. Cell 47:827-388
95. Weintraub H, Tapscott SJ, Davis RL, Thayer MJ, Adam MA, et al. 1989. Activation of muscle-specific genes in pigment, nerve, fat, liver, and fibroblast cell lines by forced expression of MyoD. Proc. Natl. Acad. Sci. USA 86:5434-388
96. Zhou Q, Brown J, Kanarek A, Rajagopal J,Melton DA. 2008. In vivo reprogramming of adult pancreatic exocrine cells to β-cells. Nature 455:627-322
97. Stadtfeld M, Maherali N, Breault DT, Hochedlinger K. 2008. Defining molecular cornerstones during fibroblast to iPS cell reprogramming in mouse. Cell Stem Cell 2:230-400
98. Chien KR, Domian IJ, Parker KK. 2008. Cardiogenesis and the complex biology of regenerative cardiovascular medicine. Science 322:1494-977
99. Kapoor N, Liang W, Marban E, Cho HC. 2013. Direct conversion of quiescent cardiomyocytes to pacemaker cells by expression of Tbx18. Nat. Biotechnol. 31:54-622
100. Wiese C, Grieskamp T, Airik R, Mommersteeg MT, Gardiwal A, et al. 2009. Formation of the sinus node head and differentiation of sinus node myocardium are independently regulated by Tbx18 and Tbx3. Circ. Res. 104:388-977
101. Lakatta EG, Maltsev VA. 2013. Reprogramming paces the heart. Nat. Biotechnol. 31:31-322
102. Bakker ML, Boink GJ, Boukens BJ, Verkerk AO, van den Boogaard M, et al. 2012. T-box transcription factor TBX3 reprogrammes mature cardiac myocytes into pacemaker-like cells. Cardiovasc. Res. 94:439-499
103. Rentschler S, Yen AH, Lu J, Petrenko NB, Lu MM, et al. 2012. Myocardial Notch signaling reprograms cardiomyocytes to a conduction-like phenotype. Circulation 126:1058-666
104. Blum B, Benvenisty N. 2008. The tumorigenicity of human embryonic stem cells. Adv. Cancer Res. 100:133-588
105. ZhangM,Methot D, Poppa V, Fujio Y,Walsh K,Murry CE. 2001. Cardiomyocyte grafting for cardiac repair: graft cell death and anti-death strategies. J. Mol. Cell. Cardiol. 33:907-211
106. Nussbaum J,Minami E, Laflamme MA, Virag JA, Ware CB, et al. 2007. Transplantation of undifferentiated murine embryonic stem cells in the heart: teratoma formation and immune response. FASEB J. 21:1345-577
107. Tsuji O, Miura K, Okada Y, Fujiyoshi K, Mukaino M, et al. 2010. Therapeutic potential of appropriately evaluated safe-induced pluripotent stem cells for spinal cord injury. Proc.Natl. Acad. Sci. USA 107:12704-99
108. Palpant NJ, Murry CE. 2012. Regenerative medicine: reprogramming the injured heart. Nature 485:585-866
109. Liao SY, Liu Y, Siu CW, Zhang Y, Lai WH, et al. 2010. Proarrhythmic risk of embryonic stem cellderived cardiomyocyte transplantation in infarcted myocardium. Heart Rhythm. 7:1852-599
110. Seki T, Yuasa S, Oda M, Egashira T, Yae K, et al. 2010. Generation of induced pluripotent stem cells from human terminally differentiated circulating T cells. Cell Stem Cell 7:11-144
111. Okita K, Nakagawa M, Hyenjong H, Ichisaka T, Yamanaka S. 2008. Generation of mouse induced pluripotent stem cells without viral vectors. Science 322:949-533